263 related articles for article (PubMed ID: 28364360)
1. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
[TBL] [Abstract][Full Text] [Related]
2. Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
Berdeja JG; Heinrich MC; Dakhil SR; Goldberg SL; Wadleigh M; Kuriakose P; Cortes J; Radich J; Helton B; Rizzieri D; Paley C; Dautaj I; Mauro MJ
Leuk Lymphoma; 2019 Oct; 60(10):2384-2393. PubMed ID: 30912699
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
4. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.
Hochhaus A; Rosti G; Cross NC; Steegmann JL; le Coutre P; Ossenkoppele G; Petrov L; Masszi T; Hellmann A; Griskevicius L; Wiktor-Jedrzejczak W; Rea D; Coriu D; Brümmendorf TH; Porkka K; Saglio G; Gastl G; Müller MC; Schuld P; Di Matteo P; Pellegrino A; Dezzani L; Mahon FX; Baccarani M; Giles FJ
Leukemia; 2016 Jan; 30(1):57-64. PubMed ID: 26437782
[TBL] [Abstract][Full Text] [Related]
5. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
[TBL] [Abstract][Full Text] [Related]
6. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akkaynak DZ; Dag IM; Ilhan O
Expert Opin Pharmacother; 2016 Oct; 17(14):1851-8. PubMed ID: 27501474
[TBL] [Abstract][Full Text] [Related]
7. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NC; Dorlhiac Llacer PE; Schwarer AP; Mahon FX; Rea D; Branford S; Purkayastha D; Collins L; Szczudlo T; Leber B
Blood; 2014 Jul; 124(5):729-36. PubMed ID: 24948656
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
9. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.
Hochhaus A; Mahon FX; le Coutre P; Petrov L; Janssen JJWM; Cross NCP; Rea D; Castagnetti F; Hellmann A; Rosti G; Gattermann N; Coronel MLP; Gutierrez MAE; Garcia-Gutierrez V; Vincenzi B; Dezzani L; Giles FJ
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1225-1233. PubMed ID: 28224300
[TBL] [Abstract][Full Text] [Related]
11. Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes.
Stuckey R; Casado LF; Colomer D; Gómez-Casares MT; Casas L; García-Gutierrez V; Sastre JL; Ramírez-Payer Á; Vall-Llovera F; Goñi MÁ; Xicoy B; Godoy AC; Núñez J; Mora I; Vallansot R; López-Lorenzo JL; Palomera L; Conesa V; Noya MS; Sánchez-Guijo F; Peña A; Bautista G; Steegmann JL
J Mol Diagn; 2020 Oct; 22(10):1217-1224. PubMed ID: 32688056
[TBL] [Abstract][Full Text] [Related]
12. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
[TBL] [Abstract][Full Text] [Related]
13. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.
Nicolini FE; Etienne G; Dubruille V; Roy L; Huguet F; Legros L; Giraudier S; Coiteux V; Guerci-Bresler A; Lenain P; Cony-Makhoul P; Gardembas M; Hermet E; Rousselot P; Amé S; Gagnieu MC; Pivot C; Hayette S; Maguer-Satta V; Etienne M; Dulucq S; Rea D; Mahon FX
Lancet Haematol; 2015 Jan; 2(1):e37-46. PubMed ID: 26687426
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
15. Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice.
Huguet F; Cayuela JM; Cambier N; Carpentier N; Tindel M; Violet I; Zunic P; Lascaux A; Etienne G;
Br J Haematol; 2019 Dec; 187(5):615-626. PubMed ID: 31394591
[TBL] [Abstract][Full Text] [Related]
16. Nilotinib in the treatment of chronic myeloid leukemia.
Sacha T; Saglio G
Future Oncol; 2019 Mar; 15(9):953-965. PubMed ID: 30547682
[TBL] [Abstract][Full Text] [Related]
17. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
Ross DM; Masszi T; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; Garcia-Gutierrez V; Gattermann N; le Coutre PD; Martino B; Saussele S; Giles FJ; Radich JP; Saglio G; Deng W; Krunic N; Bédoucha V; Gopalakrishna P; Hochhaus A
J Cancer Res Clin Oncol; 2018 May; 144(5):945-954. PubMed ID: 29468438
[TBL] [Abstract][Full Text] [Related]
18. Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients.
Park H; Kim I; Kim HJ; Shin DY; Lee SY; Kwon OH; Kim DY; Lee KH; Ahn JS; Park J; Sohn SK; Lee JO; Cheong JW; Kim KH; Kim HG; Kim H; Lee YJ; Nam SH; Do YR; Park SG; Park SK; Bae SH; Song HH; Oh D; Jung CW; Park S
Leuk Res; 2021 Dec; 111():106728. PubMed ID: 34673444
[TBL] [Abstract][Full Text] [Related]
19. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
[TBL] [Abstract][Full Text] [Related]
20. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
Noguchi S; Nakaseko C; Nishiwaki K; Ogasawara H; Ohishi K; Tokuhira M; Noguchi M; Kimura H; Handa H; Mitani K; Miura M; Wakita H; Takahashi N;
Int J Hematol; 2018 Aug; 108(2):176-183. PubMed ID: 29713954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
